The aim of the study is to investigate whether these early effects of Epo translate into improvement of mood and neurocognitive function with repeated administration in patients with treatment-resistant depression or bipolar disorder in remission and to elucidate the underlying biomarkers of potential treatment effects. The gene discussed is EPO; the disease is depressive disorder.